|
|
|
European Biopharmaceutical Review
|
| Flow cytometry is a technique for cell characterisation that is popularly used
in basic and translational research for understanding, for example, how mutated
stem cells may confer therapy resistance to a tumour (1). Alternatively, cell
characterisation can be used to measure cell receptors during activation or as
a response to immunosuppressive drugs. A flow cytometer consists of a narrow,
hydrodynamically-focused stream of cells that pass and are interrogated by a light
source. The cells’ physical characteristics of size and granularity, as well as any
fluorescent labels attached in or on the cells, scatter the beam of light. Fluorescent
labels attached will then be excited, enabling the appropriate emission
characteristics to be measured in relative terms of fluorescent intensity.
Flow cytometer manufacturers have responded to the needs of
modern researchers by developing faster systems that can measure
more variables over shorter time periods for applications such as
detecting tumour cells in peripheral blood and examining different
aspects of stem cell differentiation. However, the ability of the
software that flow cytometers rely on to analyse and visualise the
rapidly rising tide of data now being generated has lagged way
behind these improvements in instrument technology. This article
examines some of the approaches that enlightened software
manufacturers are now taking to speed up and simplify data
analysis and support the revolution in flow cytometry research. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
BioIVT Acquires UK-based Clinical Trials Laboratory Services
BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Clinical Trials Laboratory Services (CTLS), a donor center and laboratory based in London, UK. CTLS provides dedicated high-quality serum, plasma and blood collection services. It also offers full-service cell processing capabilities on site.
More info >> |
|
 |
White Papers |
 |
|
Future-proofing serialization solutions: the importance of strong level 3 capabilities
Adents
The complexities surrounding product serialization for pharmaceutical and medical device companies are immense. While current serialization requirements are limited to marking the unit of sale with a unique data carrier, by 2023 the process will require a product to be traceable through the entirety of its journey - from the individual package through the carton/pallet to its final point of distribution. In the United States, the Healthcare Distribution Management Association (HDMA) is suggesting that pharmaceutical companies begin to support this level of serialization, called aggregation, now. Around the world – in Europe and Asia in particular – disparate track and trace practices are incrementally moving toward a global standard that will, undoubtedly, be more stringent than today’s differing benchmarks. How can companies manage this transformation with the greatest degree of success while also minimizing business disruption? The key to creating an optimal implementation strategy is to select a serialization solution that has strong capabilities at all levels of technology. It’s also important to choose a solution that enables multi-phase implementation
More info >> |
|
 |
Industry Events |
 |
RDD Asia 2018
14-15 November 2018, Grand Hyatt Kochi, Kerala, India
A
must-attend meeting for pulmonary and nasal researchers, inhaled product
developers and vendors active in this important pharmaceutical niche.
More info >> |
|
|
